Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

VEGF and its soluble receptor VEGFR-2 in hypertensive disorders during pregnancy: the Indian scenario

Journal of Human Hypertension volume 26, pages 196–204 (2012)Cite this article

Abstract

Hypertensive disorders are the most common medical problem encountered during pregnancy due to defective angiogenesis during placental development. Vascular endothelial growth factor (VEGF) is one of the angiogenic growth factors that stimulates angiogenesis. The recombinant form of its soluble receptor VEGF receptor-2 (sVEGFR-2) has anti-angiogenic activity. However, there is a paucity of information on serum VEGF and sVEGFR-2 concentrations in different sub-groups of hypertensive disorders during pregnancy. In this cross-sectional study, we evaluated the concentrations and the diagnostic utility of VEGF and sVEGFR-2 in gestational hypertension (GH, n=90), pre-eclampsia (PE, n=180), eclampsia (n=90) and control (n=180) pregnancy at different gestations. VEGF levels were significantly higher in PE and eclamptic (median=19.53 pg ml−1; 60.36 pg ml−1, P=0.0001) groups as compared with the control ones (median=18 pg ml−1). But, the serum sVEGFR-2 levels were found to be significantly decreased from GH to eclampsia groups (median=5196; 3972 pg ml−1) as compared with control groups (median=7417 pg ml−1). As the gestation advanced, there was an inverse association in the serum concentrations of sVEGFR-2 among the control, GH, PE and eclampsia groups. At both ⩽34 and >34 weeks of gestations, higher sensitivity and specificity were observed for sVEGFR-2 in differentiating GH (50.8, 50%; 76.6, 76.6%), PE (63, 63%; 90, 90%) and eclampsia (65, 66.6%; 90, 90%) from the control pregnancy. This upregulation of VEGF and downregulation of sVEGFR-2 concentrations in different study groups may be due to hypoxia and could be involved intimately in the pathogenesis of these disorders. This study may contribute in understanding etio-pathogenesis of different hypertensive disorders during pregnancy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Roberts JM, Cooper DW . Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 53.

    Article  CAS  Google Scholar 

  2. National high blood pressure education program working group on high blood pressure in pregnancy. Report of the National high blood pressure education program working group on high blood pressure in pregnancy. Am J Obst Gyne 2000; 183: s1–s22.

    Article  Google Scholar 

  3. Roberts JM, Lain KY . Recent insight into the pathogenesis of pre-eclampsia. Placenta 2002; 23: 359–372.

    Article  CAS  Google Scholar 

  4. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA . Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation 2002; 9 (3): 147–160.

    Article  CAS  Google Scholar 

  5. Redman CW, Sargent IL . Latest advances in understanding pre-eclampsia. Science 2005; 8: 592–1594.

    Google Scholar 

  6. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D et al. A naturally occurring soluble form of vascular endothelial growth factor receptor-2 detected in mouse and human plasma. Mol Cancer Res 2004; 2: 315–326.

    CAS  PubMed  Google Scholar 

  7. Ferrara N, Gerber HP, LeCouter J . The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676.

    Article  CAS  Google Scholar 

  8. Agostini H, Boden K, Unsold A, Martin G, Hansen L, Fiedler U et al. A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse. Curr Eye Res 2005; 30: 249–257.

    Article  CAS  Google Scholar 

  9. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML . Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62–66.

    Article  CAS  Google Scholar 

  10. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435–439.

    Article  CAS  Google Scholar 

  11. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L et al. L, Smith LE suppression of retinal neovascularization in vivo by inhibition of VEGF using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 457–461.

    Article  Google Scholar 

  12. Rodesch F, Simon P, Donner C, Jauniaux E . Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy. Obstet Gynecol 1992; 80: 283–285.

    CAS  PubMed  Google Scholar 

  13. Ferrara N, Gerber H . The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106: 148–156.

    Article  CAS  Google Scholar 

  14. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z . Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9–22.

    Article  CAS  Google Scholar 

  15. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707–716.

    Article  CAS  PubMed Central  Google Scholar 

  16. Baker PN, Krasnow J, Roberts JM, Yeo KT . Elevated serum levels of vascular endothelial growth factor in patients with pre-eclampsia. Obstet Gynecol 1995; 86: 815–821.

    Article  CAS  Google Scholar 

  17. Sharkey AM, Cooper JC, Balmforth JR, Mclaren J, Clark DE, Charnock-Jones DS et al. Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and pregnancies complicated by pre-eclampsia. Eur J Clin Invest 1996; 26: 1182–1185.

    Article  CAS  Google Scholar 

  18. Lyall F, Greer IA, Boswell F, Fleming R . Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynecol 1997; 104: 223–228.

    Article  CAS  Google Scholar 

  19. Chaiworapongsa T, Romero R, Gotsch F, Espinoza J, Nien JK, Goncalves L et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestation age. J Matern Fetal Neonatal Med 2008; 21: 41–52.

    Article  CAS  Google Scholar 

  20. Tripathi R, Rath G, Jain A, Salhan S . Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by pre-eclampsia. Ann Anat 2008; 190: 477–489.

    Article  CAS  PubMed Central  Google Scholar 

  21. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee KY, Goncalves LF et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of pre-eclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190: 1541–1547.

    Article  CAS  PubMed Central  Google Scholar 

  22. Oh MJ, Shin JC, Popek EJ . Vascular endothelial growth factor expression in patients complicated pre-eclampsia. Korean J Obstet Gynecol 2001; 44: 1877–1882.

    Google Scholar 

  23. Lee ES, Oh MJ, Jung JW, Lim JE, Seol HJ, Lee KJ et al. The Levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by pre-eclampsia. J Korean Med Sci 2007; 22 (1): 94–98.

    Article  CAS  PubMed Central  Google Scholar 

  24. Levine RJ, Maynard SE, Qian C, Lim KH, Lucinda J, Yu KF et al. Circulating angiogenic factors and the risk of pre-eclampsia. N Engl J Med 2004; 350: 672–683.

    Article  CAS  PubMed Central  Google Scholar 

  25. Hunter A, Aitkenhead M, Caldwell C, McCracken G, Wilson D, McClure N . Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy. Hypertension 2000; 36 (6): 965–969.

    Article  CAS  PubMed Central  Google Scholar 

  26. Tammela T, Enholm B, Alitalo K, Paavonen K . The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65: 550–563.

    Article  CAS  Google Scholar 

  27. Faderl S, Do KA, Johnson MM, Keating M, O’brien S, Jilani I et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia (ALL). Blood 2005; 106: 4303–4307.

    Article  CAS  Google Scholar 

  28. Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y . Circulating angiogenic factors in pre-eclampsia, gestational proteinuria and pre-eclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 2006; 194: 551–556.

    Article  CAS  Google Scholar 

  29. Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007; 112 (1): 51–57.

    Article  CAS  Google Scholar 

  30. Kendall RL, Thomas KA . Inhibition of VEGF activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705–10709.

    Article  CAS  Google Scholar 

  31. Ebos JM, Lee CR, Bogdanovic E, Alami J, Slyke PV, Francia G et al. Vascular endothelial growth factor–mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008; 68 (2): 521–529.

    Article  CAS  Google Scholar 

  32. Rahimi N . VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci 2006; 11: 818–829.

    Article  CAS  PubMed Central  Google Scholar 

  33. Gerber HP, Condorelli F, Park J, Ferrara N . Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is upregulated by hypoxia. J Biol Chem 1997; 272: 23659–23667.

    Article  CAS  Google Scholar 

  34. Kim SY, Park SY, Kim JW, Kim YM, Yang JH, Kim MY . Circulating endothelial progenitor cells, plasma VEGF, and VEGFR-1 and VEGFR-2 levels in pre-eclampsia. Am J Obstet Gynecol 2005; 193: S74.

    Article  Google Scholar 

  35. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A . Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999–1007.

    Article  CAS  Google Scholar 

  36. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA . Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005; 366: 1797–1803.

    Article  PubMed Central  Google Scholar 

  37. Roberts DM, Kearney JB, Johnson JH, Rosenberg MP, Kumar R, Bautch VL . The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk- 1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol 2004; 164: 1531–1535.

    Article  CAS  PubMed Central  Google Scholar 

  38. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. Excess placental soluble fms-like tyrosine kinase 1(sFlt-1) may contribute to endothelial dysfunction, hypertension and proteinuria in pre-eclampsia. J Clin Invest 2003; 111: 649–658.

    Article  CAS  PubMed Central  Google Scholar 

  39. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M . A unique signal transduction from Flt tyrosine kinase, a receptor for vascular endothelial growth factor (VEGF). Oncogene 1995; 10: 135–147.

    CAS  PubMed  Google Scholar 

  40. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M . Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735–745.

    Article  CAS  PubMed Central  Google Scholar 

  41. Burton GJ, Woods AW, Jauniaux E, Kingdom JC . Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009; 30 (6): 473–482.

    Article  CAS  PubMed Central  Google Scholar 

  42. Escudero C, Puebla C, Westermeier F, Sobrevia L . Potential cell signalling mechanisms involved in differential placental angiogenesis in mild and severe pre-eclampsia. Curr Vasc Pharmacol 2009; 7 (4): 475–485.

    Article  CAS  PubMed Central  Google Scholar 

  43. Roy H, Bhardwaj S, Ylä-Herttuala S . Biology of vascular endothelial growth factors. FEBS Letters 2006; 580 (12): 2879–2887.

    Article  CAS  PubMed Central  Google Scholar 

  44. Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F et al. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 2008; 23 (6): 1407–1415.

    Article  CAS  PubMed Central  Google Scholar 

  45. Wilting J, Birkenhager R, Eichmann A, Kurz H, Martinybaron G, Marme D et al. VEGF(121) induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of the chorioallantoic membrane. Dev Biol 1996; 176: 76–85.

    Article  CAS  PubMed Central  Google Scholar 

  46. Kumazaki K, Nakayama M, Suehara N, Wada Y . Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathological conditions. Hum Pathol 2002; 33: 1069–1077.

    Article  CAS  PubMed Central  Google Scholar 

  47. Salahuddin S, Young L, Vadnais M, Benjamin P, Sachs S, Karumanchi A et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Amer J Obst Gynec 2007; 197: 28.e1–28.e6.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant of Council of Scientific and Industrial Research (CSIR Project No. 27-0133/04/EMR II), New Delhi, India. Grants: Council of scientific and Industrial Research.

Author information

Authors and Affiliations

  1. Department of Anatomy, VMMC & Safdarjang Hospital, New Delhi, India

    G Rath & R Tripathi

Authors
  1. G Rath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Tripathi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Rath.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Journal of Human Hypertension website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rath, G., Tripathi, R. VEGF and its soluble receptor VEGFR-2 in hypertensive disorders during pregnancy: the Indian scenario. J Hum Hypertens 26, 196–204 (2012). https://doi.org/10.1038/jhh.2011.17

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2011.17

Keywords

This article is cited by

Search

Advanced search

Quick links